1
|
Malek R, Sałat K, Totoson P, Karcz T, Refouvelet B, Skrzypczak-Wiercioch A, Maj M, Simakov A, Martin H, Siwek A, Szałaj N, Godyń J, Panek D, Więckowska A, Jozwiak K, Demougeot C, Kieć-Kononowicz K, Chabchoub F, Iriepa I, Marco-Contelles J, Ismaili L. Discovery of New Highly Potent Histamine H 3 Receptor Antagonists, Calcium Channel Blockers, and Acetylcholinesterase Inhibitors. ACS Chem Neurosci 2024; 15:3363-3383. [PMID: 39208251 DOI: 10.1021/acschemneuro.4c00341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/04/2024] Open
Abstract
At present, one of the most promising strategies to tackle the complex challenges posed by Alzheimer's disease (AD) involves the development of novel multitarget-directed ligands (MTDLs). To this end, we designed and synthesized nine new MTDLs using a straightforward and cost-efficient one-pot Biginelli three-component reaction. Among these newly developed compounds, one particular small molecule, named 3e has emerged as a promising MTDL. This compound effectively targets critical biological factors associated with AD, including the simultaneous inhibition of cholinesterases (ChEs), selective antagonism of H3 receptors, and blocking voltage-gated calcium channels. Additionally, compound 3e exhibited remarkable neuroprotective activity against H2O2 and Aβ1-40, and effectively restored cognitive function in AD mice treated with scopolamine in the novel object recognition task, confirming that this compound could provide a novel and innovative therapeutic approach for the effective treatment of AD.
Collapse
Affiliation(s)
- Rim Malek
- Université de Franche-Comté, INSERM, UMR 1322 LINC, F-25000 Besançon, France
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, B. P 802, Sfax 3000, Tunisia
| | - Kinga Sałat
- Department of Pharmacodynamics, Chair of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków 30-688, Poland
| | - Perle Totoson
- Université de Franche-Comté, EFS, INSERM, UMR 1098 RIGHT, F-25000 Besançon, France
| | - Tadeusz Karcz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland
| | - Bernard Refouvelet
- Université de Franche-Comté, INSERM, UMR 1322 LINC, F-25000 Besançon, France
| | - Anna Skrzypczak-Wiercioch
- University Centre of Veterinary Medicine JU-UA, University of Agriculture in Krakow, 24/28 Mickiewicz St., Kraków 30-059, Poland
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, Lublin 20-093, Poland
| | - Alexey Simakov
- Université de Franche-Comté, EFS, INSERM, UMR 1098 RIGHT, F-25000 Besançon, France
| | - Helene Martin
- Université de Franche-Comté, EFS, INSERM, UMR 1098 RIGHT, F-25000 Besançon, France
| | - Agata Siwek
- Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland
| | - Natalia Szałaj
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland
| | - Justyna Godyń
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland
| | - Dawid Panek
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland
| | - Anna Więckowska
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland
| | - Krzysztof Jozwiak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, Lublin 20-093, Poland
| | - Celine Demougeot
- Université de Franche-Comté, EFS, INSERM, UMR 1098 RIGHT, F-25000 Besançon, France
| | - Katarzyna Kieć-Kononowicz
- Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Kraków 30-688, Poland
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, B. P 802, Sfax 3000, Tunisia
| | - Isabel Iriepa
- Universidad de Alcalá. Departamento de Química Orgánica y Química Inorgánica, Alcalá de Henares, Madrid 28805, Spain
- Instituto de Investigación Química Andrés M. del Río (IQAR), Universidad de Alcalá, Alcalá de Henares, Madrid 28805, Spain, Grupo DISCOBAC, Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM)
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), C/ Juan de la Cierva 3, Madrid 28006, Spain
- CIBER, ISCIII, Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid 28006, Spain
| | - Lhassane Ismaili
- Université de Franche-Comté, INSERM, UMR 1322 LINC, F-25000 Besançon, France
| |
Collapse
|
2
|
Sharma A, Sharma M, Bharate SB. N-Benzyl piperidine Fragment in Drug Discovery. ChemMedChem 2024:e202400384. [PMID: 38924676 DOI: 10.1002/cmdc.202400384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2024] [Revised: 06/22/2024] [Accepted: 06/26/2024] [Indexed: 06/28/2024]
Abstract
The N-benzyl piperidine (N-BP) structural motif is commonly employed in drug discovery due to its structural flexibility and three-dimensional nature. Medicinal chemists frequently utilize the N-BP motif as a versatile tool to fine-tune both efficacy and physicochemical properties in drug development. It provides crucial cation-π interactions with the target protein and also serves as a platform for optimizing stereochemical aspects of potency and toxicity. This motif is found in numerous approved drugs and clinical/preclinical candidates. This review focuses on the applications of the N-BP motif in drug discovery campaigns, emphasizing its role in imparting medicinally relevant properties. The review also provides an overview of approved drugs, the clinical and preclinical pipeline, and discusses its utility for specific therapeutic targets and indications, along with potential challenges.
Collapse
Affiliation(s)
- Ankita Sharma
- Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, India
- Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Mohit Sharma
- Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, India
- Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Sandip B Bharate
- Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, India
- Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, India
- Department of Natural Products & Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500007, India
| |
Collapse
|
3
|
Pachón-Angona I, Bernard PJ, Simakov A, Maj M, Jozwiak K, Novotna A, Lemke C, Gütschow M, Martin H, Oset-Gasque MJ, Contelles JM, Ismaili L. Design and Synthesis of Multi-Functional Ligands through Hantzsch Reaction: Targeting Ca 2+ Channels, Activating Nrf2 and Possessing Cathepsin S Inhibitory, and Antioxidant Properties. Pharmaceutics 2024; 16:121. [PMID: 38258131 PMCID: PMC10819521 DOI: 10.3390/pharmaceutics16010121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 01/12/2024] [Accepted: 01/13/2024] [Indexed: 01/24/2024] Open
Abstract
This work relates to the design and synthesis of a series of novel multi-target directed ligands (MTDLs), i.e., compounds 4a-l, via a convenient one-pot three-component Hantzsch reaction. This approach targeted calcium channel antagonism, antioxidant capacity, cathepsin S inhibition, and interference with Nrf2 transcriptional activation. Of these MTDLs, 4i emerged as a promising compound, demonstrating robust antioxidant activity, the ability to activate Nrf2-ARE pathways, as well as calcium channel blockade and cathepsin S inhibition. Dihydropyridine 4i represents the first example of an MTDL that combines these biological activities.
Collapse
Affiliation(s)
- Irene Pachón-Angona
- Université de Franche-Comté, UMR INSERM 1322 LINC, F-25000 Besançon, France; (I.P.-A.); (P.J.B.)
- Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, Plaza Ramón y Cajal s/n, Ciudad Universitaria, 28040 Madrid, Spain;
| | - Paul J. Bernard
- Université de Franche-Comté, UMR INSERM 1322 LINC, F-25000 Besançon, France; (I.P.-A.); (P.J.B.)
| | - Alexey Simakov
- Université de Franche-Comté, EFS, INSERM, UMR RIGHT, F-25000 Besançon, France; (A.S.); (H.M.)
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (M.M.); (K.J.)
| | - Krzysztof Jozwiak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (M.M.); (K.J.)
| | - Anna Novotna
- Pharmaceutical Institut, An der Immenburg 4, D-53121 Bonn, Germany; (A.N.); (C.L.); (M.G.)
| | - Carina Lemke
- Pharmaceutical Institut, An der Immenburg 4, D-53121 Bonn, Germany; (A.N.); (C.L.); (M.G.)
| | - Michael Gütschow
- Pharmaceutical Institut, An der Immenburg 4, D-53121 Bonn, Germany; (A.N.); (C.L.); (M.G.)
| | - Helene Martin
- Université de Franche-Comté, EFS, INSERM, UMR RIGHT, F-25000 Besançon, France; (A.S.); (H.M.)
| | - María-Jesús Oset-Gasque
- Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, Plaza Ramón y Cajal s/n, Ciudad Universitaria, 28040 Madrid, Spain;
- Instituto Universitario de Investigación en Neuroquímica, Complutense University of Madrid, Ciudad Universitaria, 28040 Madrid, Spain
| | - José-Marco Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC) C/Juan de la Cierva 3, 28006 Madrid, Spain
- Center for Biomedical Network Research on Rare Diseases (CIBERER), CIBER, ISCIII, 28006 Madrid, Spain
| | - Lhassane Ismaili
- Université de Franche-Comté, UMR INSERM 1322 LINC, F-25000 Besançon, France; (I.P.-A.); (P.J.B.)
| |
Collapse
|
4
|
Wei W, Jing L, Tian Y, Więckowska A, Kang D, Meng B, Panek D, Godyń J, Góral I, Song Y, Liu X, Zhan P. Multifunctional agents against Alzheimer's disease based on oxidative stress: Polysubstituted pyrazine derivatives synthesized by multicomponent reactions. Bioorg Med Chem 2023; 96:117535. [PMID: 37956505 DOI: 10.1016/j.bmc.2023.117535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 11/08/2023] [Accepted: 11/08/2023] [Indexed: 11/15/2023]
Abstract
As Alzheimer's disease (AD) is a neurodegenerative disease with a complex pathogenesis, the exploration of multi-target drugs may be an effective strategy for AD treatment. Multifunctional small molecular agents can be obtained by connecting two or more active drugs or privileged pharmacophores by multicomponent reactions (MCRs). In this paper, two series of polysubstituted pyrazine derivatives with multifunctional moieties were designed as anti-AD agents and synthesized by Passerini-3CR and Ugi-4CR. Since the oxidative stress plays an important role in the pathological process of AD, the antioxidant activities of the newly synthesized compounds were first evaluated. Subsequently, selected active compounds were further screened in a series of AD-related bioassays, including Aβ1-42 self-aggregation and deaggregation, BACE-1 inhibition, metal chelation, and protection of SH-SY5Y cells from H2O2-induced oxidative damage. Compound A3B3C1 represented the best one with multifunctional potencies. Mechanism study showed that A3B3C1 acted on Nrf2/ARE signaling pathway, thus increasing the expression of related antioxidant proteins NQO1 and HO-1 to normal cell level. Furthermore, A3B3C1 showed good in vitro human plasma and liver microsome stability, indicating a potential for further development as multifunctional anti-AD agent.
Collapse
Affiliation(s)
- Wenxiu Wei
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, PR China
| | - Lanlan Jing
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, PR China
| | - Ye Tian
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, PR China; Key Laboratory for Experimental Teratology of Ministry of Education, Key Laboratory of Infection and Immunity of Shandong Province, and Department of Immunology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, PR China.
| | - Anna Więckowska
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Dongwei Kang
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, PR China
| | - Bairu Meng
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, PR China
| | - Dawid Panek
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Justyna Godyń
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Izabella Góral
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Yuning Song
- Department of Clinical Pharmacy, Qilu Hospital of Shandong University, Jinan, Shandong 250012, PR China.
| | - Xinyong Liu
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, PR China.
| | - Peng Zhan
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, PR China.
| |
Collapse
|
5
|
Duan SF, Song L, Guo HY, Deng H, Huang X, Shen QK, Quan ZS, Yin XM. Research status of indole-modified natural products. RSC Med Chem 2023; 14:2535-2563. [PMID: 38107170 PMCID: PMC10718587 DOI: 10.1039/d3md00560g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Accepted: 10/16/2023] [Indexed: 12/19/2023] Open
Abstract
Indole is a heterocyclic compound formed by the fusion of a benzene ring and pyrrole ring, which has rich biological activity. Many indole-containing compounds have been sold on the market due to their excellent pharmacological activity. For example, vincristine and reserpine have been widely used in clinical practice. The diverse structures and biological activities of natural products provide abundant resources for the development of new drugs. Therefore, this review classifies natural products by structure, and summarizes the research progress of indole-containing natural product derivatives, their biological activities, structure-activity relationship and research mechanism which has been studied in the past 13 years, so as to provide a basis for the development of new drug development.
Collapse
Affiliation(s)
- Song-Fang Duan
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Interdisciplinary Program of Biological Functional Molecules, College of Integration Science, Yanbian University Yanji 133002 China +86 0433 243 6020 +86 0433 243 6019
| | - Lei Song
- Yanbian University Hospital, Yanbian University Yanji 133002 People's Republic of China
| | - Hong-Yan Guo
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Interdisciplinary Program of Biological Functional Molecules, College of Integration Science, Yanbian University Yanji 133002 China +86 0433 243 6020 +86 0433 243 6019
| | - Hao Deng
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Interdisciplinary Program of Biological Functional Molecules, College of Integration Science, Yanbian University Yanji 133002 China +86 0433 243 6020 +86 0433 243 6019
| | - Xing Huang
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Interdisciplinary Program of Biological Functional Molecules, College of Integration Science, Yanbian University Yanji 133002 China +86 0433 243 6020 +86 0433 243 6019
| | - Qing-Kun Shen
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Interdisciplinary Program of Biological Functional Molecules, College of Integration Science, Yanbian University Yanji 133002 China +86 0433 243 6020 +86 0433 243 6019
| | - Zhe-Shan Quan
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Interdisciplinary Program of Biological Functional Molecules, College of Integration Science, Yanbian University Yanji 133002 China +86 0433 243 6020 +86 0433 243 6019
| | - Xiu-Mei Yin
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Interdisciplinary Program of Biological Functional Molecules, College of Integration Science, Yanbian University Yanji 133002 China +86 0433 243 6020 +86 0433 243 6019
| |
Collapse
|
6
|
Singh YP, Kumar H. Tryptamine: A privileged scaffold for the management of Alzheimer's disease. Drug Dev Res 2023; 84:1578-1594. [PMID: 37675624 DOI: 10.1002/ddr.22111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Revised: 08/04/2023] [Accepted: 08/25/2023] [Indexed: 09/08/2023]
Abstract
Alzheimer's disease (AD) is a chronic and irreversible neurodegenerative disease associated with aging. It is characterized by the progressive loss of memory and other cognitive functions. Although the exact etiology of AD is not well explored, several factors, such as the deposition of amyloid-β (Aβ) plaques, hyperphosphorylation of tau protein, presence of low levels of acetylcholine, and generation of oxidative stress, are key mediators in the progression of AD. Currently, the clinical treatment options for AD are limited and are based on cholinesterase (ChE) inhibitors (e.g., donepezil, rivastigmine, and galantamine), N-methyl- d-aspartic acid receptor antagonists (e.g., memantine), and the recently approved Aβ modulator (e.g., aducanumab). Tryptamine (2-(1H-indol-3-yl)ethan-1-amine) is a small molecule that contains an indole nucleus and an ethylamine side chain. It is also the active metabolite of tryptophan. It possesses a wide range of biological activities related to neurodegenerative disorders, such as ChE inhibition, Aβ aggregation inhibition, antioxidant effects, monoamine-oxidase inhibition, and neuroprotection. Several tryptamine-based hybrid analogs are currently being investigated as multifunctional agents for the development of novel hybrids for AD treatment. Thus, this review article aims to provide in-depth insights into the research progress and strategies for designing multifunctional agents used in Alzheimer's therapy.
Collapse
Affiliation(s)
- Yash P Singh
- Department of Anatomy and Neurobiology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland, USA
| | - Harish Kumar
- Government College of Pharmacy, Shimla, Himachal Pradesh, India
- Department of Technical Education Vocational and Industrial Training, Sunder Nagar, Himachal Pradesh, India
| |
Collapse
|
7
|
Dakhlaoui I, Bernard PJ, Pietrzak D, Simakov A, Maj M, Refouvelet B, Béduneau A, Cornu R, Jozwiak K, Chabchoub F, Iriepa I, Martin H, Marco-Contelles J, Ismaili L. Exploring the Potential of Sulfonamide-Dihydropyridine Hybrids as Multitargeted Ligands for Alzheimer's Disease Treatment. Int J Mol Sci 2023; 24:ijms24119742. [PMID: 37298693 DOI: 10.3390/ijms24119742] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 05/25/2023] [Accepted: 05/31/2023] [Indexed: 06/12/2023] Open
Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease that has a heavy social and economic impact on all societies and for which there is still no cure. Multitarget-directed ligands (MTDLs) seem to be a promising therapeutic strategy for finding an effective treatment for this disease. For this purpose, new MTDLs were designed and synthesized in three steps by simple and cost-efficient procedures targeting calcium channel blockade, cholinesterase inhibition, and antioxidant activity. The biological and physicochemical results collected in this study allowed us the identification two sulfonamide-dihydropyridine hybrids showing simultaneous cholinesterase inhibition, calcium channel blockade, antioxidant capacity and Nrf2-ARE activating effect, that deserve to be further investigated for AD therapy.
Collapse
Affiliation(s)
- Imen Dakhlaoui
- Laboratoire LINC UR 481, Pôle de Chimie Médicinale, Université de Franche-Comté, F-25000 Besançon, France
- Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, B. P 802, Sfax 3000, Tunisia
| | - Paul J Bernard
- Laboratoire LINC UR 481, Pôle de Chimie Médicinale, Université de Franche-Comté, F-25000 Besançon, France
| | - Diana Pietrzak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland
| | - Alexey Simakov
- PEPITE EA4267, Université de Franche-Comté, F-25000 Besançon, France
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland
| | - Bernard Refouvelet
- Laboratoire LINC UR 481, Pôle de Chimie Médicinale, Université de Franche-Comté, F-25000 Besançon, France
| | - Arnaud Béduneau
- PEPITE EA4267, Université de Franche-Comté, F-25000 Besançon, France
| | - Raphaël Cornu
- PEPITE EA4267, Université de Franche-Comté, F-25000 Besançon, France
| | - Krzysztof Jozwiak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, B. P 802, Sfax 3000, Tunisia
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, Universidad de Alcalá, Ctra. Madrid-Barcelona, Km. 33,6, 28871 Alcalá de Henares, Spain
| | - Helene Martin
- PEPITE EA4267, Université de Franche-Comté, F-25000 Besançon, France
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - Lhassane Ismaili
- Laboratoire LINC UR 481, Pôle de Chimie Médicinale, Université de Franche-Comté, F-25000 Besançon, France
| |
Collapse
|
8
|
Kılıçaslan D, Kurt AH, Köse M, Çeşme M, Güngör Ö, Oztabag CK, Doganer A. A Novel Donepezil–Caffeic Acid Hybrid: Synthesis, Biological Evaluation, and Molecular Docking Studies. BIOCHEMISTRY (MOSCOW) 2023; 88:50-63. [PMID: 37068881 DOI: 10.1134/s0006297923010054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
A novel donepezil-caffeic acid (DP-CA) hybrid molecule was designed, synthesis, and investigated by molecular modeling. Its biological activity and protective effect were investigated by the IR spectroscopy, 1H and 13C NMR spectroscopy, and mass spectrometry. DP-CA was highly active against acetylcholine esterase and inhibited it at the micromolar concentrations. Fluorescence and UV-Vis spectroscopy studies showed strong binding of DP-CA to DNA. Moreover, DP-CA exhibited protective effects against H2O2-induced toxicity in U-118 MG glioblastoma cells. Finally, molecular docking showed a high affinity of DP-CA in all concentrations, and the active 4EY7 site exhibited essential residues with polar and apolar contacts. Taken together, these findings indicate that DP-CA could be a prospective multifunctional agent for the treatment of neurodegenerative diseases.
Collapse
Affiliation(s)
- Derya Kılıçaslan
- Afsin Vocational School, Department of Chemistry and Chemical Processing Technologies, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey.
| | - Akif Hakan Kurt
- Department of Pharmacology, Faculty of Medicine, Bolu Abant Izzet Baysal University, Bolu, Turkey
| | - Muhammet Köse
- Department of Chemistry, Faculty of Art and Sciences, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
| | - Mustafa Çeşme
- Department of Chemistry, Faculty of Art and Sciences, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
| | - Özge Güngör
- Department of Chemistry, Faculty of Art and Sciences, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
| | - Cansu Kara Oztabag
- Department of Interdisciplinary Neuroscience, Bolu Abant Izzet Baysal University, Institute of Health Sciences, Bolu, Turkey
| | - Adem Doganer
- Department Biostatistics and Medical Informatics, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
| |
Collapse
|
9
|
Eissa KI, Kamel MM, Mohamed LW, Kassab AE. Development of new Alzheimer's disease drug candidates using donepezil as a key model. Arch Pharm (Weinheim) 2023; 356:e2200398. [PMID: 36149034 DOI: 10.1002/ardp.202200398] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 09/03/2022] [Accepted: 09/05/2022] [Indexed: 01/04/2023]
Abstract
Alzheimer's disease (AD) is one of the most prevalent geriatric diseases and a significant cause of high mortality. This crippling disorder is becoming more prevalent at an unprecedented rate, which has led to an increase in the financial cost of caring. It is a pathologically complicated, multifactorial disease characterized by β-amyloid precipitation, β-amyloid oligomer production, decrease in cholinergic function, and dysregulation of other neurotransmitter systems. Due to the pathogenic complexity of AD, multitarget drugs that can simultaneously alternate multiple biological targets may enhance the therapeutic efficacy. Donepezil (DNP) is the most potent approved drug for the treatment of AD. It has a remarkable effect on a number of AD-related processes, including cholinesterase activity, anti-Aβ aggregation, oxidative stress, and more. DNP resembles an excellent scaffold to be hybridized with other pharmacophoric moieties having biological activity against AD pathological factors. There have been significant attempts made to modify the structure of DNP to create new bioactive chemical entities with novel structural patterns. In this review, we highlight recent advances in the development of multiple-target DNP-hybridized models for the treatment of AD that can be used in the future in the rational design of new potential AD therapeutics. The design and development of new drug candidates for the treatment of AD using DNP as a molecular scaffold have also been reviewed and summarized.
Collapse
Affiliation(s)
- Kholoud I Eissa
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Mona M Kamel
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Lamia W Mohamed
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Asmaa E Kassab
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| |
Collapse
|
10
|
Malek R, Simakov A, Davis A, Maj M, Bernard PJ, Wnorowski A, Martin H, Marco-Contelles J, Chabchoub F, Dallemagne P, Rochais C, Jozwiak K, Ismaili L. Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules 2022; 28:molecules28010071. [PMID: 36615267 PMCID: PMC9822022 DOI: 10.3390/molecules28010071] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Revised: 12/16/2022] [Accepted: 12/19/2022] [Indexed: 12/24/2022] Open
Abstract
Novel multitarget-directed ligands BIGI 4a-d and BIGI 5a-d were designed and synthesized with a simple and cost-efficient procedure via a one-pot three-component Biginelli reaction targeting acetyl-/butyrylcholinesterases inhibition, calcium channel antagonism, and antioxidant ability. Among these multitarget-directed ligands, BIGI 4b, BIGI 4d, and BIGI 5b were identified as promising new hit compounds showing in vitro balanced activities toward the recognized AD targets. In addition, these compounds showed suitable physicochemical properties and a good druglikeness score predicted by Data Warrior software.
Collapse
Affiliation(s)
- Rim Malek
- Laboratoire LINC UR 481, Pôle de Chimie Médicinale, University Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax 3000, Tunisia
| | - Alexey Simakov
- PEPITE EA4267, University Franche-Comté, F-25000 Besançon, France
| | - Audrey Davis
- Centre d’Etudes et de Recherche sur le Médicament de Normandie, Normandie University, Unicaen, CERMN, 14000 Caen, France
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland
| | - Paul J. Bernard
- Laboratoire LINC UR 481, Pôle de Chimie Médicinale, University Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| | - Artur Wnorowski
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland
| | - Helene Martin
- PEPITE EA4267, University Franche-Comté, F-25000 Besançon, France
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), C/ Juan de la Cierva 3, 28006 Madrid, Spain
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax 3000, Tunisia
| | - Patrick Dallemagne
- Centre d’Etudes et de Recherche sur le Médicament de Normandie, Normandie University, Unicaen, CERMN, 14000 Caen, France
| | - Christophe Rochais
- Centre d’Etudes et de Recherche sur le Médicament de Normandie, Normandie University, Unicaen, CERMN, 14000 Caen, France
| | - Krzysztof Jozwiak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland
| | - Lhassane Ismaili
- Laboratoire LINC UR 481, Pôle de Chimie Médicinale, University Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
- Correspondence:
| |
Collapse
|
11
|
Pasquereau S, Galais M, Bellefroid M, Pachón Angona I, Morot-Bizot S, Ismaili L, Van Lint C, Herbein G. Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro. Sci Rep 2022; 12:20309. [PMID: 36434137 PMCID: PMC9700709 DOI: 10.1038/s41598-022-24682-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Accepted: 11/18/2022] [Indexed: 11/27/2022] Open
Abstract
A novel coronavirus, SARS-CoV-2, emerged in China at the end of 2019 causing a large global outbreak. As treatments are of the utmost importance, drugs with broad anti-coronavirus activity embody a rich and rapid drug discovery landscape, where candidate drug compounds could be identified and optimized. To this end, we tested ten small-molecules with chemical structures close to ferulic acid derivatives (FADs) (n = 8), caffeic acid derivatives (CAFDs) (n = 1) and carboxamide derivatives (CAMDs) (n = 1) for their ability to reduce HCoV-229E replication, another member of the coronavirus family. Among these ten drugs tested, five of them namely MBA112, MBA33, MBA27-1, OS4-1 and MBA108-1 were highly cytotoxic and did not warrant further testing. In contrast, we observed a moderate cytotoxicity for two of them, MBA152 and 5c. Three drugs, namely MBA140, LIJ2P40, and MBA28 showed lower cytotoxicity. These candidates were then tested for their antiviral propreties against HCoV-229E and SARS-CoV2 replication. We first observed encouraging results in HCoV-229E. We then measured a reduction of the viral SARS-CoV2 replication by 46% with MBA28 (EC50 > 200 µM), by 58% with MBA140 (EC50 = 176 µM), and by 82% with LIJ2P40 (EC50 = 66.5 µM). Overall, the FAD LIJ2P40 showed a reduction of the viral titer on SARS-CoV-2 up to two logs with moderate cytotoxicity which opens the door to further evaluation to fight Covid-19.
Collapse
Affiliation(s)
- Sébastien Pasquereau
- grid.7459.f0000 0001 2188 3779Pathogens and Inflammation/EPILAB Laboratory, EA 4266, Université de Franche-Comté, Université Bourgogne Franche-Comté (UBFC), Besançon, France
| | - Mathilde Galais
- grid.4989.c0000 0001 2348 0746Service of Molecular Virology, Department of Molecular Biology (DBM), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium
| | - Maxime Bellefroid
- grid.4989.c0000 0001 2348 0746Service of Molecular Virology, Department of Molecular Biology (DBM), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium
| | - Irene Pachón Angona
- grid.493090.70000 0004 4910 6615Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, Besançon, France
| | | | - Lhassane Ismaili
- grid.493090.70000 0004 4910 6615Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, Besançon, France
| | - Carine Van Lint
- grid.4989.c0000 0001 2348 0746Service of Molecular Virology, Department of Molecular Biology (DBM), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium
| | - Georges Herbein
- grid.7459.f0000 0001 2188 3779Pathogens and Inflammation/EPILAB Laboratory, EA 4266, Université de Franche-Comté, Université Bourgogne Franche-Comté (UBFC), Besançon, France ,grid.411158.80000 0004 0638 9213Department of Virology, CHU Besançon, Besançon, France
| |
Collapse
|
12
|
Multicomponent reactions as a privileged tool for multitarget-directed ligand strategies in Alzheimer's disease therapy. Future Med Chem 2022; 14:1583-1606. [PMID: 36263996 DOI: 10.4155/fmc-2022-0170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Among neurodegenerative pathologies affecting the older population, Alzheimer's disease is the most common type of dementia and leads to neurocognitive and behavioral disorders. It is a complex and progressive age-related multifactorial disease characterized by a series of highly interconnected pathophysiological processes. Within the last decade, the multitarget-directed ligand strategy has emerged as a viable approach to developing complex molecules that exhibit several pharmacophores which can target the different enzymes and receptors involved in the pathogenesis of the disease. Herein, we focus on using multicomponent reactions such as Hantzsch, Biginelli and Ugi to develop these biologically active multitopic ligands.
Collapse
|
13
|
Carbamate-based N-Substituted Tryptamine Derivatives as Novel Pleiotropic Molecules for Alzheimer's Disease. Bioorg Chem 2022; 125:105844. [DOI: 10.1016/j.bioorg.2022.105844] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 02/17/2022] [Accepted: 04/23/2022] [Indexed: 12/22/2022]
|
14
|
Kaur R, Sood A, Lang DK, Arora R, Kumar N, Diwan V, Saini B. Natural Products as Sources of Multitarget Compounds: Advances in the Development of Ferulic Acid as Multitarget Therapeutic. Curr Top Med Chem 2022; 22:347-365. [PMID: 35040403 DOI: 10.2174/1568026622666220117105740] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 11/25/2021] [Accepted: 12/27/2021] [Indexed: 11/22/2022]
Abstract
Nature has provided therapeutic substances for millennia, with many valuable medications derived from plant sources. Multitarget drugs become essential in the management of various disorders including hepatic disorders, neurological disorders, diabetes, and carcinomas. Ferulic acid is a significant potential therapeutic agent, which is easily available at low cost, possesses a low toxicity profile, and has minimum side effects. Ferulic acid exhibits various therapeutic actions by modulation of various signal transduction pathways such as Nrf2, p38, and mTOR. The actions exhibited by ferulic acid include anti-apoptosis, antioxidant, anti-inflammatory, antidiabetic, anticarcinogenic, hepatoprotection, cardioprotection, activation of transcriptional factors, expression of genes, regulation of enzyme activity, and neuroprotection, which further help in treating various pathophysiological conditions such as cancer, skin diseases, brain disorders, diabetes, Parkinson's disease, Alzheimer's disease, hypoxia, hepatic disorders, H1N1 flu, and viral infections. The current review focuses on the significance of natural products as sources of multitarget compounds and a primary focus has been made on ferulic acid and its mechanism, role, and protective action in various ailments.
Collapse
Affiliation(s)
- Rajwinder Kaur
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | - Ankita Sood
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | | | - Rashmi Arora
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| | - Neeraj Kumar
- National Institute of Pharmaceutical Education and Research, Hyderabad, India
| | - Vishal Diwan
- Centre for Chronic Disease, The University of Queensland, Australia
| | - Balraj Saini
- Chitkara College of Pharmacy, Chitkara University, Punjab, India
| |
Collapse
|
15
|
Turkez H, Arslan ME, Barboza JN, Kahraman CY, de Sousa DP, Mardinoğlu A. Therapeutic Potential of Ferulic Acid in Alzheimer's Disease. Curr Drug Deliv 2021; 19:860-873. [PMID: 34963433 DOI: 10.2174/1567201819666211228153801] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 08/16/2021] [Accepted: 10/27/2021] [Indexed: 11/22/2022]
Abstract
Alzheimer's Disease (AD) is one of the most important neurodegenerative diseases and it covers 60% of whole dementia cases. AD is a constantly progressing neurodegenerative disease as a result of the production of β-amyloid (Aβ) protein and the accumulation of hyper-phosphorylated Tau protein; it causes breakages in the synaptic bonds and neuronal deaths to a large extent. Millions of people worldwide suffer from AD because there is no definitive drug for disease prevention, treatment or slowdown. Over the last decade, multiple target applications have been developed for AD treatments. These targets include Aβ accumulations, hyper-phosphorylated Tau proteins, mitochondrial dysfunction, and oxidative stress resulting in toxicity. Various natural or semisynthetic antioxidant formulations have been shown to protect brain cells from Aβ induced toxicity and provide promising potentials for AD treatment. Ferulic acid (FA), a high-capacity antioxidant molecule, is naturally synthesized from certain plants. FA has been shown to have different substantial biological properties, such as anticancer, antidiabetic, antimicrobial, anti-inflammatory, hepatoprotective, and cardioprotective actions, etc. Furthermore, FA exerted neuroprotection via preventing Aβ-fibril formation, acting as an anti-inflammatory agent, and inhibiting free radical generation and acetylcholinesterase (AChE) enzyme activity. In this review, we present key biological roles of FA and several FA derivatives in Aβ-induced neurotoxicity, protection against free radical attacks, and enzyme inhibitions and describe them as possible therapeutic agents for the treatment of AD.
Collapse
Affiliation(s)
- Hasan Turkez
- Department of Medical Biology, Faculty of Medicine, Atatürk University, 25240, Erzurum, Turkey
- Department of Pharmacy, University G. d'Annunzio Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy
| | - Mehmet Enes Arslan
- Department of Molecular Biology and Genetics, Erzurum Technical University, 25200, Erzurum, Turkey
| | - Joice Nascimento Barboza
- Department of Pharmaceutical Sciences, Federal University of Paraíba, 58051-970, João Pessoa, PB, Brazil
| | - Cigdem Yuce Kahraman
- Department of Medical Genetics, Faculty of Medicine, Atatürk University, 25240, Erzurum, Turkey
| | - Damiao Pergentino de Sousa
- Department of Pharmaceutical Sciences, Federal University of Paraíba, 58051-970, João Pessoa, PB, Brazil
| | - Adil Mardinoğlu
- Science for Life Laboratory, KTH-Royal Institute of Technology, Stockholm, SE-17121, Sweden
- Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, SE1 9RT, United Kingdom
| |
Collapse
|
16
|
Gulcan HO, Kosar M. The hybrid compounds as multi-target ligands for the treatment of Alzheimer's Disease: Considerations on Donepezil. Curr Top Med Chem 2021; 22:395-407. [PMID: 34766890 DOI: 10.2174/1568026621666211111153626] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 08/31/2021] [Accepted: 11/11/2021] [Indexed: 11/22/2022]
Abstract
The strategies to combat Alzheimer's Disease (AD) have been changing with respect to the failures of many drug candidates assessed in clinical studies, the complex pathophysiology of AD, and the limitations of the current drugs employed. So far, none of the targets, either validated or nonvalidated, have been shown to be purely causative in the generation and development of AD. Considering the progressive and the neurodegenerative characteristics of the disease, the main strategy has been based on the design of molecules capable of showing activity on more than one receptor, and it is defined as multi-target ligand design strategy. The hybrid molecule concept is an outcome of this approach. Donepezil, as one of the currently employed drugs for AD therapy, has also been utilized in hybrid drug design studies. This review has aimed to present the promising donepezil-like hybrid molecules introduced in the recent period. Particularly, multi-target ligands with additional activities concomitant to cholinesterase inhibition are preferred.
Collapse
Affiliation(s)
- Hayrettin Ozan Gulcan
- Faculty of Pharmacy, Eastern Mediterranean University, Famagusta, T.R. North Cyprus, via Mersin 10, Turkey
| | - Muberra Kosar
- Faculty of Pharmacy, Eastern Mediterranean University, Famagusta, T.R. North Cyprus, via Mersin 10, Turkey
| |
Collapse
|
17
|
Gardelly M, Trimech B, Horchani M, Znati M, Jannet HB, Romdhane A. Anti-tyrosinase and Anti-butyrylcholinesterase Quinolines-Based Coumarin Derivatives: Synthesis and Insights from Molecular Docking Studies. CHEMISTRY AFRICA 2021. [PMCID: PMC7938276 DOI: 10.1007/s42250-021-00235-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In this work, a series of anti-tyrosinase and anti-butyrylcholinesterase coumarin derivatives 4a–f and 5a–f were synthesized starting from 4-hydroxycoumarin. The condensation of 2-(arylimin)-4-hydroxycoumarins 3a–f with dimethylformamide dimethyl acetal (DMF-DMA), used as a key reaction, afforded the precursors 4a–f, whose acid treatment led to the formation of 5a–f. These prepared heterocycles were characterized by spectroscopic means including 1H-NMR, 13C-NMR, and DCI-HRMS. Their anti-tyrosinase and anti-butyrylcholinesterase activities have been evaluated in vitro and some of them exhibited promising activity supported by the molecular docking analysis to estimate possible interactions between these compounds and active sites of both proteins tyrosinase (PDB: 2Y9W) and butyrylcholinesterase (PDB: 4TPK).
Collapse
Affiliation(s)
- Marwa Gardelly
- Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Faculty of Science of Monastir, Team: Medicinal Chemistry and Natural Products, Avenue of Environment, University of Monastir, 5019 Monastir, Tunisia
| | - Belsem Trimech
- Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Faculty of Science of Monastir, Team: Medicinal Chemistry and Natural Products, Avenue of Environment, University of Monastir, 5019 Monastir, Tunisia
| | - Mabrouk Horchani
- Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Faculty of Science of Monastir, Team: Medicinal Chemistry and Natural Products, Avenue of Environment, University of Monastir, 5019 Monastir, Tunisia
| | - Mansour Znati
- Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Faculty of Science of Monastir, Team: Medicinal Chemistry and Natural Products, Avenue of Environment, University of Monastir, 5019 Monastir, Tunisia
| | - Hichem Ben Jannet
- Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Faculty of Science of Monastir, Team: Medicinal Chemistry and Natural Products, Avenue of Environment, University of Monastir, 5019 Monastir, Tunisia
| | - Anis Romdhane
- Laboratory of Heterocyclic Chemistry, Natural Products and Reactivity, Faculty of Science of Monastir, Team: Medicinal Chemistry and Natural Products, Avenue of Environment, University of Monastir, 5019 Monastir, Tunisia
| |
Collapse
|
18
|
Synthesis of new Hantzsch adducts showing Ca 2+ channel blockade capacity, cholinesterase inhibition and antioxidant power. Future Med Chem 2021; 13:1717-1729. [PMID: 34402661 DOI: 10.4155/fmc-2021-0176] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Background: Alzheimer's disease is a chronic neurodegenerative chronic disease with a heavy social and economic impact in our developed societies, which still lacks an efficient therapy. Method: This paper describes the Hantzsch multicomponent synthesis of twelve alkyl hexahydro-quinoline-3-carboxylates, 4a-l, along with the evaluation of their Ca2+ channel blockade capacity, cholinesterase inhibition and antioxidant power. Results: Compound 4l showed submicromolar inhibition of butyrylcholinesterase, Ca2+ channel antagonism and an antioxidant effect. Conclusion: Compound 4l is an interesting compound that deserves further investigation for Alzheimer's disease therapy.
Collapse
|
19
|
Ismaili L, Monnin J, Etievant A, Arribas RL, Viejo L, Refouvelet B, Soukup O, Janockova J, Hepnarova V, Korabecny J, Kucera T, Jun D, Andrys R, Musilek K, Baguet A, García-Frutos EM, De Simone A, Andrisano V, Bartolini M, de los Ríos C, Marco-Contelles J, Haffen E. (±)- BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3β Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease. ACS Chem Neurosci 2021; 12:1328-1342. [PMID: 33797877 DOI: 10.1021/acschemneuro.0c00803] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Multitarget-directed ligands (MTDLs) are considered a promising therapeutic strategy to address the multifactorial nature of Alzheimer's disease (AD). Novel MTDLs have been designed as inhibitors of human acetylcholinesterases/butyrylcholinesterases, monoamine oxidase A/B, and glycogen synthase kinase 3β and as calcium channel antagonists via the Biginelli multicomponent reaction. Among these MTDLs, (±)-BIGI-3h was identified as a promising new hit compound showing in vitro balanced activities toward the aforementioned recognized AD targets. Additional in vitro studies demonstrated antioxidant effects and brain penetration, along with the ability to inhibit the aggregation of both τ protein and β-amyloid peptide. The in vivo studies have shown that (±)-BIGI-3h (10 mg/kg intraperitoneally) significantly reduces scopolamine-induced cognitive deficits.
Collapse
Affiliation(s)
- Lhassane Ismaili
- Neurosciences intégratives et cliniques EA 481, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France
| | - Julie Monnin
- Neurosciences intégratives et cliniques EA 481, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France
| | - Adeline Etievant
- Neurosciences intégratives et cliniques EA 481, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France
| | - Raquel L. Arribas
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - Lucía Viejo
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - Bernard Refouvelet
- Neurosciences intégratives et cliniques EA 481, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France
| | - Ondrej Soukup
- Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic, University of Defence, 50003 Hradec Kralove, Czech Republic
| | - Jana Janockova
- Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic, University of Defence, 50003 Hradec Kralove, Czech Republic
| | - Vendula Hepnarova
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, 66210 Brno, Czech Republic
| | - Jan Korabecny
- Biomedical Research Center, University Hospital Hradec Kralove, Czech Republic, University of Defence, 50003 Hradec Kralove, Czech Republic
| | - Tomas Kucera
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, 66210 Brno, Czech Republic
| | - Daniel Jun
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, 66210 Brno, Czech Republic
| | - Rudolf Andrys
- Faculty of Science, Department of Chemistry, University Hradec Kralove, Rokitanskeho 62, 50003 Hradec Kralove, Czech Republic
| | - Kamil Musilek
- Faculty of Science, Department of Chemistry, University Hradec Kralove, Rokitanskeho 62, 50003 Hradec Kralove, Czech Republic
| | - Aurelie Baguet
- Université Bourgogne Franche Comté, INSERM, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France
| | - Eva M. García-Frutos
- Instituto de Ciencia de Materiales de Madrid, CSIC, Cantoblanco, 28049 Madrid, Spain
| | - Angela De Simone
- Department for Life Quality Studies, Alma Mater Studiorum University of Bologna, Corso di Augusto, 237, 47921 Rimini, Italy
| | - Vincenza Andrisano
- Department for Life Quality Studies, Alma Mater Studiorum University of Bologna, Corso di Augusto, 237, 47921 Rimini, Italy
| | - Manuela Bartolini
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
| | - Cristóbal de los Ríos
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry, Instituto de Química Orgánica General, Consejo Superior de Investigaciones Científicas, Juan de la Cierva 3, 28006 Madrid, Spain
| | - Emmanuel Haffen
- Neurosciences intégratives et cliniques EA 481, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France
| |
Collapse
|
20
|
Moni L, Banfi L, Basso A, Mori A, Risso F, Riva R, Lambruschini C. A Thorough Study on the Photoisomerization of Ferulic Acid Derivatives. European J Org Chem 2021. [DOI: 10.1002/ejoc.202100064] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Lisa Moni
- Department of Chemistry and Industrial Chemistry University of Genova Via Dodecaneso, 31 16146 Genova Italy
| | - Luca Banfi
- Department of Chemistry and Industrial Chemistry University of Genova Via Dodecaneso, 31 16146 Genova Italy
| | - Andrea Basso
- Department of Chemistry and Industrial Chemistry University of Genova Via Dodecaneso, 31 16146 Genova Italy
| | - Alessia Mori
- Department of Chemistry and Industrial Chemistry University of Genova Via Dodecaneso, 31 16146 Genova Italy
| | - Federica Risso
- Department of Chemistry and Industrial Chemistry University of Genova Via Dodecaneso, 31 16146 Genova Italy
| | - Renata Riva
- Department of Chemistry and Industrial Chemistry University of Genova Via Dodecaneso, 31 16146 Genova Italy
| | - Chiara Lambruschini
- Department of Chemistry and Industrial Chemistry University of Genova Via Dodecaneso, 31 16146 Genova Italy
| |
Collapse
|
21
|
Kareem RT, Abedinifar F, Mahmood EA, Ebadi AG, Rajabi F, Vessally E. The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's agents: highlights from 2010 to 2020. RSC Adv 2021; 11:30781-30797. [PMID: 35498922 PMCID: PMC9041380 DOI: 10.1039/d1ra03718h] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Accepted: 08/14/2021] [Indexed: 11/21/2022] Open
Abstract
Dementia is a term used to define different brain disorders that affect memory, thinking, behavior, and emotion. Alzheimer's disease (AD) is the second cause of dementia that is generated by the death of cholinergic neurons (especially acetylcholine (ACh)), which have a vital role in cognition. Acetylcholinesterase inhibitors (AChEI) affect acetylcholine levels in the brain and are broadly used to treat Alzheimer's. Donepezil, rivastigmine, and galantamine, which are FDA-approved drugs for AD, are cholinesterase inhibitors. In addition, scientists are attempting to develop hybrid molecules and multi-target-directed ligands (MTDLs) that can simultaneously modulate multiple biological targets. This review highlights recent examples of MTDLs and fragment-based strategy in the rational design of new potential AD medications from 2010 onwards. This review highlights recent examples of multi-target-directed ligands (MTDLs) based on donepezil structure modification from 2010 onwards.![]()
Collapse
Affiliation(s)
- Rzgar Tawfeeq Kareem
- Department of Chemistry, College of Science, University of Bu Ali Sina, Hamadan, Iran
| | - Fahimeh Abedinifar
- School of Chemistry, College of Science, University of Tehran, Tehran, Iran
| | - Evan Abdolkareem Mahmood
- College of Health Sciences, University of Human Development, Sulaimaniyah, Kurdistan region of Iraq
| | - Abdol Ghaffar Ebadi
- Department of Agriculture, Jouybar Branch, Islamic Azad University, Jouybar, Iran
| | - Fatemeh Rajabi
- Department of Chemistry, Payame Noor University, P.O. Box 19395-3697, Tehran, Iran
| | - Esmail Vessally
- Department of Chemistry, Payame Noor University, P.O. Box 19395-3697, Tehran, Iran
| |
Collapse
|
22
|
Przybyłowska M, Dzierzbicka K, Kowalski S, Chmielewska K, Inkielewicz-Stepniak I. Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. Curr Neuropharmacol 2021; 19:1323-1344. [PMID: 33342413 PMCID: PMC8719290 DOI: 10.2174/1570159x19666201218103434] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 10/07/2020] [Accepted: 11/29/2020] [Indexed: 11/22/2022] Open
Abstract
The aim of this work is to review tacrine analogues from the last three years, which were not included in the latest review work, donepezil and galantamine hybrids from 2015 and rivastigmine derivatives from 2014. In this account, we summarize the efforts toward the development and characterization of non-toxic inhibitors of cholinesterases based on mentioned drugs with various interesting additional properties such as antioxidant, decreasing β-amyloid plaque aggregation, nitric oxide production, pro-inflammatory cytokines release, monoamine oxidase-B activity, cytotoxicity and oxidative stress in vitro and in animal model that classify these hybrids as potential multifunctional therapeutic agents for Alzheimer's disease. Moreover, herein, we have described the cholinergic hypothesis, mechanisms of neurodegeneration and current pharmacotherapy of Alzheimer's disease based on the restoration of cholinergic function through blocking enzymes that break down acetylcholine.
Collapse
Affiliation(s)
- Maja Przybyłowska
- Department of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, Poland
| | - Krystyna Dzierzbicka
- Department of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, Poland
| | - Szymon Kowalski
- Department of Pharmaceutical Pathophysiology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland
| | - Klaudia Chmielewska
- Department of Organic Chemistry, Faculty of Chemistry, Gdansk University of Technology, Gdansk, Poland
| | - Iwona Inkielewicz-Stepniak
- Department of Pharmaceutical Pathophysiology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland
| |
Collapse
|
23
|
Pachón Angona I, Martin H, Daniel S, Moraleda I, Bonet A, Wnorowski A, Maj M, Jozwiak K, Iriepa I, Refouvelet B, Marco-Contelles J, Ismaili L. Synthesis of Hantzsch Adducts as Cholinesterases and Calcium Flux inhibitors, Antioxidants and Neuroprotectives. Int J Mol Sci 2020; 21:ijms21207652. [PMID: 33081112 PMCID: PMC7589057 DOI: 10.3390/ijms21207652] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 10/09/2020] [Accepted: 10/14/2020] [Indexed: 01/22/2023] Open
Abstract
We report herein the design, synthesis, biological evaluation, and molecular modelling of new inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), able to block Ca+2 channels also showing antioxidant and neuroprotective activities. The new MTDL, dialkyl 2,6-dimethyl-4-(4-((5-aminoalkyl)oxy)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3a-p, have been obtained via Hantzsch reaction from appropriate and commercially available precursors. Pertinent biological analysis has prompted us to identify MTDL 3h [dimethyl-4-(4-((5-(4-benzylpiperidin-1-yl)pentyl)oxy)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate] as an attractive inhibitor of AChE (1.8 μM) and BuChE (2 μM), Ca+2 channel antagonist (47.72% at 10 μM), and antioxidant (2.54 TE) agent, showing significant neuroprotection 28.68% and 38.29% against H2O2, and O/R, respectively, at 0.3 μM, thus being considered a hit-compound for further investigation in our search for anti-Alzheimer's disease agents.
Collapse
Affiliation(s)
- Irene Pachón Angona
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
| | - Helene Martin
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France; (H.M.); (A.B.)
| | - Solene Daniel
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry, School Sciences, University of Alcalá, Ctra. Barcelona, Km. 33.6, 28871 Alcalá de Henares, Spain;
| | - Alexandre Bonet
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France; (H.M.); (A.B.)
| | - Artur Wnorowski
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Krzysztof Jozwiak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, School Sciences, University of Alcalá, Ctra. Barcelona, Km. 33.6, 28871 Alcalá de Henares, Spain;
- Correspondence: (I.I.); (B.R.); (L.I.)
| | - Bernard Refouvelet
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
- Correspondence: (I.I.); (B.R.); (L.I.)
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), Juan de la Cierva, 3, 28006-Madrid, Spain;
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.)
- Correspondence: (I.I.); (B.R.); (L.I.)
| |
Collapse
|
24
|
Ghotbi G, Mahdavi M, Najafi Z, Moghadam FH, Hamzeh-Mivehroud M, Davaran S, Dastmalchi S. Design, synthesis, biological evaluation, and docking study of novel dual-acting thiazole-pyridiniums inhibiting acetylcholinesterase and β-amyloid aggregation for Alzheimer’s disease. Bioorg Chem 2020; 103:104186. [DOI: 10.1016/j.bioorg.2020.104186] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2020] [Revised: 07/15/2020] [Accepted: 08/12/2020] [Indexed: 01/13/2023]
|
25
|
Triazolopyridopyrimidine: A New Scaffold for Dual-Target Small Molecules for Alzheimer's Disease Therapy. Molecules 2020; 25:molecules25143190. [PMID: 32668671 PMCID: PMC7397274 DOI: 10.3390/molecules25143190] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 07/09/2020] [Accepted: 07/12/2020] [Indexed: 12/02/2022] Open
Abstract
Alzheimer’s disease (AD) is multifactorial disease characterized by the accumulation of abnormal extracellular deposits of amyloid-beta (Aβ) peptide, and intracellular neurofibrillary tangles (NFTs), along with dramatic neuronal death and decreased levels of choline acetyltransferase. Given the limited therapeutic success of available drugs, it is urgent to explore all the opportunities available to combat this illness. Among them, the discovery of new heterocyclic scaffolds binding different receptors involved in AD should offer structural diversity and new therapeutic solutions. In this context, this work describes new triazolopyridopyrimidine easily prepared in good yields showing anticholinesterase inhibition and strong antioxidant power, particularly the most balanced: 6-amino-5-(4-methoxyphenyl)-2-phenyl-[1,2,4]triazolo[1′,5′:1,6] pyrido[2,3-d]pyrimidine-4-carbonitrile(3c) with IC50 equal to 1.32 μM against AChE and oxygen radical absorbance capacity (ORAC) value equal to 4.01 Trolox equivalents (TE); thus representing a new and very promising hit-triazolopyridopyrimidine for AD therapy.
Collapse
|
26
|
Sang Z, Wang K, Bai P, Wu A, Shi J, Liu W, Zhu G, Wang Y, Lan Y, Chen Z, Zhao Y, Qiao Z, Wang C, Tan Z. Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem 2020; 194:112265. [DOI: 10.1016/j.ejmech.2020.112265] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 03/19/2020] [Accepted: 03/20/2020] [Indexed: 12/20/2022]
|
27
|
Pachòn Angona I, Daniel S, Martin H, Bonet A, Wnorowski A, Maj M, Jóźwiak K, Silva TB, Refouvelet B, Borges F, Marco-Contelles J, Ismaili L. Design, Synthesis and Biological Evaluation of New Antioxidant and Neuroprotective Multitarget Directed Ligands Able to Block Calcium Channels. Molecules 2020; 25:molecules25061329. [PMID: 32183349 PMCID: PMC7144121 DOI: 10.3390/molecules25061329] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 03/12/2020] [Accepted: 03/12/2020] [Indexed: 01/08/2023] Open
Abstract
We report herein the design, synthesis and biological evaluation of new antioxidant and neuroprotective multitarget directed ligands (MTDLs) able to block Ca2+ channels. New dialkyl 2,6-dimethyl-4-(4-(prop-2-yn-1-yloxy)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate MTDLs 3a–t, resulting from the juxtaposition of nimodipine, a Ca2+ channel antagonist, and rasagiline, a known MAO inhibitor, have been obtained from appropriate and commercially available precursors using a Hantzsch reaction. Pertinent biological analysis has prompted us to identify the MTDL 3,5-dimethyl-2,6–dimethyl–4-[4-(prop–2–yn–1-yloxy)phenyl]-1,4-dihydro- pyridine- 3,5-dicarboxylate (3a), as an attractive antioxidant (1.75 TE), Ca2+ channel antagonist (46.95% at 10 μM), showing significant neuroprotection (38%) against H2O2 at 10 μM, being considered thus a hit-compound for further investigation in our search for anti-Alzheimer’s disease agents.
Collapse
Affiliation(s)
- Irene Pachòn Angona
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.); (B.R.)
| | - Solene Daniel
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.); (B.R.)
| | - Helene Martin
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France; (H.M.); (A.B.)
| | - Alexandre Bonet
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France; (H.M.); (A.B.)
| | - Artur Wnorowski
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Maciej Maj
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Krzysztof Jóźwiak
- Department of Biopharmacy, Medical University of Lublin, ul. W. Chodzki 4a, 20-093 Lublin, Poland; (A.W.); (M.M.); (K.J.)
| | - Tiago Barros Silva
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, R. Campo Alegre 1021/1055, 4169-007 Porto, Portugal; (T.B.S.); (F.B.)
| | - Bernard Refouvelet
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.); (B.R.)
| | - Fernanda Borges
- CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, R. Campo Alegre 1021/1055, 4169-007 Porto, Portugal; (T.B.S.); (F.B.)
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), Juan de la Cierva, 3, 28006 Madrid, Spain
- Correspondence: (J.M.-C.); (L.I.)
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Univ. Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France; (I.P.A.); (S.D.); (B.R.)
- Correspondence: (J.M.-C.); (L.I.)
| |
Collapse
|
28
|
Mohsin NUA, Ahmad M. Donepezil: A review of the recent structural modifications and their impact on anti-Alzheimer activity. BRAZ J PHARM SCI 2020. [DOI: 10.1590/s2175-97902019000418325] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|
29
|
Pourshojaei Y, Eskandari K, Asadipour A. Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents. Mini Rev Med Chem 2019; 19:1577-1598. [DOI: 10.2174/1389557519666190719143112] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2018] [Revised: 06/02/2019] [Accepted: 06/25/2019] [Indexed: 12/19/2022]
Abstract
:
Alzheimer, a progressive disease, is a common term for memory loss which interferes with
daily life through severe influence on cognitive abilities. Based on the cholinergic hypothesis, and Xray
crystallographic determination of the structure of acetylcholinesterase (AChE) enzyme, the level of
acetylcholine (ACh, an important neurotransmitter associated with memory) in the hippocampus and
cortex area of the brain has a direct effect on Alzheimer. This fact encourages scientists to design and
synthesize a wide range of acetylcholinesterase inhibitors (AChEIs) to control the level of ACh in the
brain, keeping in view the crystallographic structure of AChE enzyme and drugs approved by the Food
and Drug Administration (FDA).
:
AChEIs have slightly diverse pharmacological properties, but all of them work by inhibiting the segregation
of ACh by blocking AChE. We reviewed significant scaffolds introduced as AChEIs. In some
studies, the activity against butyrylcholinesterase (BuChE) has been evaluated as well because BuChE
is a similar enzyme to neuronal acetylcholinesterase and is capable of hydrolyzing ACh. In order to
study AChEIs effectively, we divided them structurally into 12 classes and briefly explained effective
AChEIs and compared their activities against AChE enzyme.
Collapse
Affiliation(s)
- Yaghoub Pourshojaei
- Department of Medicinal Chemistry, Faculty of Pharmacy & Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| | - Khalil Eskandari
- Department of Medicinal Chemistry, Faculty of Pharmacy & Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| | - Ali Asadipour
- Department of Medicinal Chemistry, Faculty of Pharmacy & Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| |
Collapse
|
30
|
Pachón-Angona I, Refouvelet B, Andrýs R, Martin H, Luzet V, Iriepa I, Moraleda I, Diez-Iriepa D, Oset-Gasque MJ, Marco-Contelles J, Musilek K, Ismaili L. Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy. J Enzyme Inhib Med Chem 2019; 34:479-489. [PMID: 30712420 PMCID: PMC6366423 DOI: 10.1080/14756366.2018.1545766] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 10/21/2018] [Accepted: 11/04/2018] [Indexed: 12/13/2022] Open
Abstract
We describe herein the design, multicomponent synthesis and biological studies of new donepezil + chromone + melatonin hybrids as potential agents for Alzheimer's disease (AD) therapy. We have identified compound 14n as promising multitarget small molecule showing strong BuChE inhibition (IC50 = 11.90 ± 0.05 nM), moderate hAChE (IC50 = 1.73 ± 0.34 μM), hMAO A (IC50 = 2.78 ± 0.12 μM), and MAO B (IC50 = 21.29 ± 3.85 μM) inhibition, while keeping a strong antioxidant power (3.04 TE, ORAC test). Consequently, the results reported here support the development of new multitarget Donepezil + Chromone + Melatonin hybrids, such as compound 14n, as a potential drug for AD patients cure.
Collapse
Affiliation(s)
- Irene Pachón-Angona
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Bernard Refouvelet
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Rudolf Andrýs
- Faculty of Science, Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Helène Martin
- PEPITE EA4267, Laboratoire de Toxicologie Cellulaire, University Bourgogne Franche-Comté, Besançon, France
| | - Vincent Luzet
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
- Institute of Chemical Research Andrés M. del Río, Alcalà University, Madrid, Spain
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
| | - Daniel Diez-Iriepa
- Department of Organic Chemistry and Inorganic Chemistry, Alcalà University, Madrid, Spain
- Institute of Chemical Research Andrés M. del Río, Alcalà University, Madrid, Spain
| | - María-Jesús Oset-Gasque
- Instituto de Investigación en Neuroquímica, Universidad Complutense de Madrid, Madrid, Spain
- Department of Biochemistry and Molecular Biology, School of Pharmacy, Plaza de Ramòn y Cajal, Madrid, Spain
| | | | - Kamil Musilek
- Faculty of Science, Department of Chemistry, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Lhassane Ismaili
- Neurosciences intégratives et cliniques, Pôle Chimie Organique et Thérapeutique, University Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|
31
|
Malek R, Arribas RL, Palomino-Antolin A, Totoson P, Demougeot C, Kobrlova T, Soukup O, Iriepa I, Moraleda I, Diez-Iriepa D, Godyń J, Panek D, Malawska B, Głuch-Lutwin M, Mordyl B, Siwek A, Chabchoub F, Marco-Contelles J, Kiec-Kononowicz K, Egea J, de los Ríos C, Ismaili L. New Dual Small Molecules for Alzheimer’s Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase Inhibition. J Med Chem 2019; 62:11416-11422. [DOI: 10.1021/acs.jmedchem.9b00937] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Rim Malek
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Université Bourgogne Franche-Comté, UFR Santé, 19, Rue Ambroise Paré, F-25000 Besançon, France
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, University of Sfax, B. P 802, 3000 Sfax, Tunisia
| | - Raquel L. Arribas
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - Alejandra Palomino-Antolin
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
- Molecular Neuroinflammation and Neuronal Plasticity Laboratory, Research Unit, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
- Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, 28006 Madrid, Spain
| | - Perle Totoson
- EA4267 PEPITE, Université Bourgogne Franche-Comté, F-25030, Besançon, France
| | - Celine Demougeot
- EA4267 PEPITE, Université Bourgogne Franche-Comté, F-25030, Besançon, France
| | - Tereza Kobrlova
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, CZ-500 01 Hradec Kralove, Czech Republic
- Biomedical Research Center, University Hospital CZ-500 05 Hradec Kralove, Czech Republic
| | - Ondrej Soukup
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, CZ-500 01 Hradec Kralove, Czech Republic
- Biomedical Research Center, University Hospital CZ-500 05 Hradec Kralove, Czech Republic
| | | | | | - Daniel Diez-Iriepa
- Laboratory of Medicinal Chemistry, IQOG, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain
| | - Justyna Godyń
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Dawid Panek
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Malawska
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Monika Głuch-Lutwin
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Barbara Mordyl
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Agata Siwek
- Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers, University of Sfax, B. P 802, 3000 Sfax, Tunisia
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry, IQOG, CSIC, Juan de la Cierva 3, 28006 Madrid, Spain
| | | | - Javier Egea
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
- Molecular Neuroinflammation and Neuronal Plasticity Laboratory, Research Unit, Hospital Universitario Santa Cristina, 28009 Madrid, Spain
- Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, 28006 Madrid, Spain
| | - Cristóbal de los Ríos
- Servicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, C/Diego de León, 62, 28006 Madrid, Spain
- Instituto Teofilo Hernando, Universidad Autónoma de Madrid, C/Arzobispo Morcillo, 4, 28029 Madrid, Spain
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481, Pôle de Chimie Organique et Thérapeutique, Université Bourgogne Franche-Comté, UFR Santé, 19, Rue Ambroise Paré, F-25000 Besançon, France
| |
Collapse
|
32
|
Malek R, Refouvelet B, Benchekroun M, Iriepa I, Moraleda I, Andrys R, Musilek K, Marco-Contelles J, Ismaili L. Synthesis and Biological Evaluation of Novel Chromone+Donepezil Hybrids for Alzheimer’s Disease Therapy. Curr Alzheimer Res 2019; 16:815-820. [DOI: 10.2174/1567205016666191011112624] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 07/10/2019] [Accepted: 08/16/2019] [Indexed: 01/18/2023]
Abstract
Background:
Many factors are involved in Alzheimer’s Disease (AD) such as amyloid
plaques, neurofibrillary tangles, cholinergic deficit and oxidative stress. To counter the complexity of the
disease the new approach for drug development is to create a single molecule able to act simultaneously
on different targets.
Objective:
We conceived eight drug likeliness compounds targeting the inhibition of cholinesterases and
the scavenging of radicals.
Methods:
We synthesised the new molecules by the Passerini multicomponent reaction and evaluated
their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) as well
as their antioxidant activities by the Oxygen Radical Absorbance Capacity (ORAC) assay. The lipinski’s
rule for drug likeness and in silico ADME prediction was also performed.
Results:
Compounds 4f [IC50 (EeAChE) = 0.30 μM; IC50 (eqBuChE) = 0.09 μM; ORAC = 0.64 TE]
and 4h [IC50 (EeAChE) = 1 μM; IC50 (eqBuChE) = 0.03 μM; ORAC = 0.50 TE] were identified as hits
for further development.
Conclusion:
The Passerini reaction allowed us the facile synthesis of ditarget molecules of interest for
the treatment of AD.
Collapse
Affiliation(s)
- Rim Malek
- Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| | - Bernard Refouvelet
- Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| | - Mohamed Benchekroun
- Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| | - Isabel Iriepa
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain
| | - Ignacio Moraleda
- Departamento de Química Orgánica y Química Inorgánica, Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain
| | - Rudolf Andrys
- University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, Hradec Kralove, Czech Republic
| | - Kamil Musilek
- University of Hradec Kralove, Faculty of Science, Department of Chemistry, Rokitanskeho 62, Hradec Kralove, Czech Republic
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC), Juan de la Cierva 3; 28006-Madrid, Spain
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques, Pôle Chimie Organique et Thérapeutique, EA 481, University, Bourgogne Franche-Comté, UFR Santé, 19, rue Ambroise Paré, F-25000 Besançon, France
| |
Collapse
|
33
|
Babaee S, Zolfigol MA, Zarei M, Abbasi M, Najafi Z. Synthesis of pyridinium-based salts: Catalytic application at the synthesis of six membered O-heterocycles. MOLECULAR CATALYSIS 2019. [DOI: 10.1016/j.mcat.2019.110403] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
34
|
Malek R, Maj M, Wnorowski A, Jóźwiak K, Martin H, Iriepa I, Moraleda I, Chabchoub F, Marco-Contelles J, Ismaili L. Multi-target 1,4-dihydropyridines showing calcium channel blockade and antioxidant capacity for Alzheimer’s disease therapy. Bioorg Chem 2019; 91:103205. [DOI: 10.1016/j.bioorg.2019.103205] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 07/19/2019] [Accepted: 08/14/2019] [Indexed: 11/17/2022]
|
35
|
Benchekroun M, Pachón-Angona I, Luzet V, Martin H, Oset-Gasque MJ, Marco-Contelles J, Ismaili L. Synthesis, antioxidant and Aβ anti-aggregation properties of new ferulic, caffeic and lipoic acid derivatives obtained by the Ugi four-component reaction. Bioorg Chem 2019; 85:221-228. [DOI: 10.1016/j.bioorg.2018.12.029] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 12/17/2018] [Accepted: 12/19/2018] [Indexed: 12/31/2022]
|
36
|
Mishra P, Kumar A, Panda G. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018). Bioorg Med Chem 2019; 27:895-930. [DOI: 10.1016/j.bmc.2019.01.025] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 01/15/2019] [Accepted: 01/23/2019] [Indexed: 01/09/2023]
|
37
|
Dgachi Y, Martin H, Malek R, Jun D, Janockova J, Sepsova V, Soukup O, Iriepa I, Moraleda I, Maalej E, Carreiras MC, Refouvelet B, Chabchoub F, Marco-Contelles J, Ismaili L. Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy. J Enzyme Inhib Med Chem 2019; 34:163-170. [PMID: 30482062 PMCID: PMC6263107 DOI: 10.1080/14756366.2018.1538136] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
In view of the multifactorial nature of Alzheimer’s disease (AD), multitarget small molecules (MTSM) represent the most potent and attractive therapeutic strategy to design new drugs for Alzheimer’s disease therapy. The new MTSM KojoTacrines (KTs) were designed and synthesized by juxtaposition of selected pharmacophoric motifs from kojic acid and tacrine. Among them, 11-amino-2-(hydroxymethyl)-12-(3-methoxyphenyl)-7,9,10,12-tetrahydropyrano [2',3':5,6] pyrano[2,3-b]quinolin-4(8H)-one (KT2d) was identified as less-hepatotoxic than tacrine, at higher concentration, a moderate, but selective human acetylcholinesterase inhibitor (IC50 = 4.52 ± 0.24 µM), as well as an antioxidant agent (TE = 4.79) showing significant neuroprotection against Aβ1–40 at 3 µM and 10 µM concentrations. Consequently, KT2d is a potential new hit-ligand for AD therapy for further biological exploration.
Collapse
Affiliation(s)
- Youssef Dgachi
- a Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax , University of Sfax , Sfax , Tunisia.,b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Hélène Martin
- c Laboratoire de Toxicologie Cellulaire , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Rim Malek
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Daniel Jun
- d Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Jana Janockova
- e Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Vendula Sepsova
- d Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , University of Defence , Hradec Kralove , Czech Republic
| | - Ondrej Soukup
- e Biomedical Research Center , University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Isabel Iriepa
- f Department of Organic Chemistry and Inorganic Chemistry, School of Biology, Environmental Sciences and Chemistry , University of Alcalá , Alcalá de Henares , Spain
| | - Ignacio Moraleda
- f Department of Organic Chemistry and Inorganic Chemistry, School of Biology, Environmental Sciences and Chemistry , University of Alcalá , Alcalá de Henares , Spain
| | - Emna Maalej
- g Laboratoire Matériaux, Traitement et Analyse (LMTA) , Institut National de Recherche et d'Analyse Physico-chimique Technopole , Ariana-Tunis , Tunisia
| | - M Carmo Carreiras
- h Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy , Universidade de Lisboa , Lisboa , Portugal
| | - Bernard Refouvelet
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| | - Fakher Chabchoub
- a Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax , University of Sfax , Sfax , Tunisia
| | | | - Lhassane Ismaili
- b Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques EA 481 , Univ. Bourgogne Franche-Comté , Besançon , France
| |
Collapse
|
38
|
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease. Eur J Med Chem 2018; 158:463-477. [PMID: 30243151 DOI: 10.1016/j.ejmech.2018.09.031] [Citation(s) in RCA: 132] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Revised: 07/03/2018] [Accepted: 09/10/2018] [Indexed: 12/19/2022]
Abstract
Alzheimer's disease (AD) is one of the most common neurodegenerative disorders in elderly people. Considering the multifactorial nature of AD, the concept of multi-target-directed ligands (MTDLs) has recently emerged as a new strategy for designing therapeutic agents on AD. MTDLs are confirmed to simultaneously affect diverse targets which contribute to etiology of AD. As the most potent approved drug, donepezil affects various events of AD, like inhibiting cholinesterases activities, anti-Aβ aggregation, anti-oxidative stress et al. Modifications of donepezil or hybrids with pharmacophores of donepezil in recent five years are summarized in this article. On the basis of case studies, our concerns and opinions about development of donepezil derivatives, designing of MTDLs, and perspectives for AD treatments are discussed in final part.
Collapse
|
39
|
Mezeiova E, Spilovska K, Nepovimova E, Gorecki L, Soukup O, Dolezal R, Malinak D, Janockova J, Jun D, Kuca K, Korabecny J. Profiling donepezil template into multipotent hybrids with antioxidant properties. J Enzyme Inhib Med Chem 2018. [PMID: 29529892 PMCID: PMC6009928 DOI: 10.1080/14756366.2018.1443326] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Alzheimer’s disease is debilitating neurodegenerative disorder in the elderly. Current therapy relies on administration of acetylcholinesterase inhibitors (AChEIs) -donepezil, rivastigmine, galantamine, and N-methyl-d-aspartate receptor antagonist memantine. However, their therapeutic effect is only short-term and stabilizes cognitive functions for up to 2 years. Given this drawback together with other pathological hallmarks of the disease taken into consideration, novel approaches have recently emerged to better cope with AD onset or its progression. One such strategy implies broadening the biological profile of AChEIs into so-called multi-target directed ligands (MTDLs). In this review article, we made comprehensive literature survey emphasising on donepezil template which was structurally converted into plethora of MTLDs preserving anti-cholinesterase effect and, at the same time, escalating the anti-oxidant potential, which was reported as a crucial role in the pathogenesis of the Alzheimer’s disease.
Collapse
Affiliation(s)
- Eva Mezeiova
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,b National Institute of Mental Health , Klecany , Czech Republic
| | - Katarina Spilovska
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,b National Institute of Mental Health , Klecany , Czech Republic.,d Department of Chemistry , University of Hradec Kralove , Hradec Kralove , Czech Republic
| | - Eugenie Nepovimova
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,c Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , Hradec Kralove , Czech Republic.,d Department of Chemistry , University of Hradec Kralove , Hradec Kralove , Czech Republic
| | - Lukas Gorecki
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,c Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , Hradec Kralove , Czech Republic
| | - Ondrej Soukup
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,b National Institute of Mental Health , Klecany , Czech Republic
| | - Rafael Dolezal
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - David Malinak
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,d Department of Chemistry , University of Hradec Kralove , Hradec Kralove , Czech Republic
| | - Jana Janockova
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic
| | - Daniel Jun
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,c Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , Hradec Kralove , Czech Republic
| | - Kamil Kuca
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,d Department of Chemistry , University of Hradec Kralove , Hradec Kralove , Czech Republic
| | - Jan Korabecny
- a Biomedical Research Centre, University Hospital Hradec Kralove , Hradec Kralove , Czech Republic.,c Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences , Hradec Kralove , Czech Republic
| |
Collapse
|
40
|
Zhang X, He X, Chen Q, Lu J, Rapposelli S, Pi R. A review on the hybrids of hydroxycinnamic acid as multi-target-directed ligands against Alzheimer’s disease. Bioorg Med Chem 2018; 26:543-550. [DOI: 10.1016/j.bmc.2017.12.042] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Revised: 12/14/2017] [Accepted: 12/24/2017] [Indexed: 01/31/2023]
|
41
|
Chioua M, Serrano E, Dgachi Y, Martin H, Jun D, Janockova J, Sepsova V, Soukup O, Moraleda I, Chabchoub F, Ismaili L, Iriepa I, Marco-Contelles J. Synthesis, Biological Assessment and Molecular Modeling of Racemic QuinoPyranoTacrines
for Alzheimer's Disease Therapy. ChemistrySelect 2018. [DOI: 10.1002/slct.201702781] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Mourad Chioua
- Laboratory of Medicinal Chemistry (IQOG, CSIC); Juan de la Cierva, 3 28006-Madrid Spain
| | - Estefanía Serrano
- Laboratory of Medicinal Chemistry (IQOG, CSIC); Juan de la Cierva, 3 28006-Madrid Spain
- Department of Organic Chemistry and Inorganic Chemistry; School of Biology; Enviromental Sciences and Chemistry; University of Alcalá, Ctra. Barcelona; Km. 33.6 28871 Alcalá de Henares Spain
| | - Youssef Dgachi
- Laboratory of Applied Chemistry: Heterocycles; Lipids and Polymers; Faculty of Sciences of Sfax; University of Sfax. B. P 802. 3000 Sfax-; Tunisia
| | - Hélène Martin
- PEPITE EA4267; Laboratoire de Toxicologie Cellulaire; Univ. Bourgogne Franche-Comté, F-; 25000 Besançon France
| | - Daniel Jun
- Department of Toxicology and Military Pharmacy; Faculty of Military Health Sciences; University of Defence; Hradec Kralove Czech Republic
| | - Jana Janockova
- Biomedical Research Center; University Hospital Hradec Kralove; Czech Republic
| | - Vendula Sepsova
- Department of Toxicology and Military Pharmacy; Faculty of Military Health Sciences; University of Defence; Hradec Kralove Czech Republic
| | - Ondrej Soukup
- Biomedical Research Center; University Hospital Hradec Kralove; Czech Republic
| | - Ignacio Moraleda
- Department of Organic Chemistry and Inorganic Chemistry; School of Biology; Enviromental Sciences and Chemistry; University of Alcalá, Ctra. Barcelona; Km. 33.6 28871 Alcalá de Henares Spain
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry: Heterocycles; Lipids and Polymers; Faculty of Sciences of Sfax; University of Sfax. B. P 802. 3000 Sfax-; Tunisia
| | - Lhassane Ismaili
- Laboratoire de Chimie Organique et Thérapeutique; Neurosciences intégratives et cliniques EA 481; Univ. Franche-Comté; Univ. Bourgogne Franche-Comté; UFR SMP, 19, rue Ambroise Paré F-25000 Besançon France
| | - Isabel Iriepa
- Department of Organic Chemistry and Inorganic Chemistry; School of Biology; Enviromental Sciences and Chemistry; University of Alcalá, Ctra. Barcelona; Km. 33.6 28871 Alcalá de Henares Spain
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC); Juan de la Cierva, 3 28006-Madrid Spain
| |
Collapse
|
42
|
Zribi L, Zribi F, Marco-Contelles J, Chabchoub F, Ismaili L. Facile one-pot synthesis of new [1,2,4]triazolo[1,5-a]pyridine derivatives by ultrasonic irradiation. SYNTHETIC COMMUN 2017. [DOI: 10.1080/00397911.2017.1357078] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Lazhar Zribi
- Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax, Tunisia
| | - Fathi Zribi
- Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax, Tunisia
| | | | - Fakher Chabchoub
- Laboratory of Applied Chemistry, Heterocycles, Lipids and Polymers, Faculty of Sciences of Sfax, University of Sfax, Sfax, Tunisia
| | - Lhassane Ismaili
- Laboratoire de Chimie Organique et Thérapeutique, Neurosciences Intégratives et Cliniques, University of Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|
43
|
New (benz)imidazolopyridino tacrines as nonhepatotoxic, cholinesterase inhibitors for Alzheimer disease. Future Med Chem 2017; 9:723-729. [DOI: 10.4155/fmc-2017-0019] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Aim: Due to the multifactorial nature of Alzheimer’s disease, there is an urgent search for new more efficient, multitarget-directed drugs. Results: This paper describes the synthesis, antioxidant and in vitro biological evaluation of ten (benz)imidazopyridino tacrines (7–16), showing less toxicity than tacrine at high doses, and potent cholinesterase inhibitory capacity, in the low micromolar range. Among them, compound 10 is a nonhepatotoxic tacrine at 1000 mM, showing moderate, but totally selective electric eel acetylcholinesterase inhibition, whereas molecule 16 is twofold less toxic than tacrine at 1000 μM, showing moderate and almost equipotent inhibition for electric eel acetylcholinesterase and equine butyrylcholinesterase. Conclusion: (Benz)imidazopyridino tacrines (7–16) have been identified as a new and promising type of tacrines for the potential treatment of Alzheimer’s disease.
Collapse
|
44
|
Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Prog Neurobiol 2017; 151:4-34. [DOI: 10.1016/j.pneurobio.2015.12.003] [Citation(s) in RCA: 87] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 11/11/2015] [Accepted: 12/11/2015] [Indexed: 01/16/2023]
|
45
|
Dias KST, de Paula CT, dos Santos T, Souza IN, Boni MS, Guimarães MJ, da Silva FM, Castro NG, Neves GA, Veloso CC, Coelho MM, de Melo ISF, Giusti FC, Giusti-Paiva A, da Silva ML, Dardenne LE, Guedes IA, Pruccoli L, Morroni F, Tarozzi A, Viegas C. Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease. Eur J Med Chem 2017; 130:440-457. [DOI: 10.1016/j.ejmech.2017.02.043] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2016] [Revised: 02/15/2017] [Accepted: 02/17/2017] [Indexed: 01/04/2023]
|
46
|
Tetrahydropyranodiquinolin-8-amines as new, non hepatotoxic, antioxidant, and acetylcholinesterase inhibitors for Alzheimer's disease therapy. Eur J Med Chem 2017; 126:576-589. [DOI: 10.1016/j.ejmech.2016.11.050] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Revised: 11/21/2016] [Accepted: 11/22/2016] [Indexed: 11/21/2022]
|
47
|
Wu MY, Esteban G, Brogi S, Shionoya M, Wang L, Campiani G, Unzeta M, Inokuchi T, Butini S, Marco-Contelles J. Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation. Eur J Med Chem 2016; 121:864-879. [DOI: 10.1016/j.ejmech.2015.10.001] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2015] [Revised: 09/09/2015] [Accepted: 10/01/2015] [Indexed: 12/31/2022]
|
48
|
Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer's Disease. Molecules 2016; 21:molecules21050634. [PMID: 27187348 PMCID: PMC6273488 DOI: 10.3390/molecules21050634] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Revised: 04/19/2016] [Accepted: 05/04/2016] [Indexed: 11/16/2022] Open
Abstract
We report herein the straightforward two-step synthesis and biological assessment of novel racemic benzochromenopyrimidinones as non-hepatotoxic, acetylcholinesterase inhibitors with antioxidative properties. Among them, compound 3Bb displayed a mixed-type inhibition of human acetylcholinesterase (IC50 = 1.28 ± 0.03 μM), good antioxidant activity, and also proved to be non-hepatotoxic on human HepG2 cell line.
Collapse
|
49
|
Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics. Future Med Chem 2016; 8:697-711. [DOI: 10.4155/fmc-2016-0003] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Alzheimer's disease is a multifactorial syndrome, for which effective cures are urgently needed. Seeking for enhanced therapeutic efficacy, multitarget drugs have been increasingly sought after over the last decades. They offer the attractive prospect of tackling intricate network effects, but with the benefits of a single-molecule therapy. Herein, we highlight relevant progress in the field, focusing on acetylcholinesterase inhibition and amyloid pathways as two pivotal features in multitarget design strategies. We also discuss the intertwined relationship between selected molecular targets and give a brief glimpse into the power of multitarget agents as pharmacological probes of Alzheimer's disease molecular mechanisms.
Collapse
|
50
|
Dgachi Y, Ismaili L, Knez D, Benchekroun M, Martin H, Szałaj N, Wehle S, Bautista-Aguilera OM, Luzet V, Bonnet A, Malawska B, Gobec S, Chioua M, Decker M, Chabchoub F, Marco-Contelles J. Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aβ1−42Aggregation Inhibitors for Alzheimer's Disease Therapy. ChemMedChem 2016; 11:1318-27. [DOI: 10.1002/cmdc.201500539] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Youssef Dgachi
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers; Faculty of Sciences of Sfax; University of Sfax; BP 802 3000 Sfax Tunisia
| | - Lhassane Ismaili
- Neurosciences Intégratives et Cliniques EA 481; Laboratoire de Chimie Organique et Thérapeutique, UFR SMP; Université de Franche-Comté; Université Bourgogne Franche-Comté; 19 rue Ambroise Paré 25000 Besançon France
| | - Damijan Knez
- Faculty of Pharmacy; University of Ljubljana; Aškerčeva 7 1000 Ljubljana Slovenia
| | - Mohamed Benchekroun
- Neurosciences Intégratives et Cliniques EA 481; Laboratoire de Chimie Organique et Thérapeutique, UFR SMP; Université de Franche-Comté; Université Bourgogne Franche-Comté; 19 rue Ambroise Paré 25000 Besançon France
| | - Hélène Martin
- Laboratory of Cell Toxicology, EA 4267; University of Franche-Comté; 19 rue Ambroise Paré 25030 Besançon France
| | - Natalia Szałaj
- Department of Physicochemical Drug Analysis; Jagiellonian University, Medical College; Medyczna 9 Street 30-688 Krakow Poland
| | - Sarah Wehle
- Pharmazeutische und Medizinische Chemie; Institut für Pharmazie und Lebensmittelchemie; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Oscar M. Bautista-Aguilera
- Neurosciences Intégratives et Cliniques EA 481; Laboratoire de Chimie Organique et Thérapeutique, UFR SMP; Université de Franche-Comté; Université Bourgogne Franche-Comté; 19 rue Ambroise Paré 25000 Besançon France
| | - Vincent Luzet
- Neurosciences Intégratives et Cliniques EA 481; Laboratoire de Chimie Organique et Thérapeutique, UFR SMP; Université de Franche-Comté; Université Bourgogne Franche-Comté; 19 rue Ambroise Paré 25000 Besançon France
| | - Alexandre Bonnet
- Laboratory of Cell Toxicology, EA 4267; University of Franche-Comté; 19 rue Ambroise Paré 25030 Besançon France
| | - Barbara Malawska
- Department of Physicochemical Drug Analysis; Jagiellonian University, Medical College; Medyczna 9 Street 30-688 Krakow Poland
| | - Stanislav Gobec
- Faculty of Pharmacy; University of Ljubljana; Aškerčeva 7 1000 Ljubljana Slovenia
| | - Mourad Chioua
- Laboratory of Medicinal Chemistry (IQOG, CSIC); C/Juan de la Cierva 3 28006 Madrid Spain
| | - Michael Decker
- Pharmazeutische und Medizinische Chemie; Institut für Pharmazie und Lebensmittelchemie; Julius-Maximilians-Universität Würzburg; Am Hubland 97074 Würzburg Germany
| | - Fakher Chabchoub
- Laboratory of Applied Chemistry: Heterocycles, Lipids and Polymers; Faculty of Sciences of Sfax; University of Sfax; BP 802 3000 Sfax Tunisia
| | - José Marco-Contelles
- Laboratory of Medicinal Chemistry (IQOG, CSIC); C/Juan de la Cierva 3 28006 Madrid Spain
| |
Collapse
|